A study in mice reveals key interactions between proteins involved in fibroblast growth factor signaling and how they contribute to distinct stages of eye lens development.

Savolitinib NDA accepted by the NMPA with Priority Review status and Breakthrough Therapy designation for 2L EGFRm NSCLC patients with MET amplification, in combination with TAGRISSO ® (osimertinib), ...

As one of the most common subtypes of breast cancer, patients with hormone receptor-positive (HR+) breast cancer usually experience disease progression over an extended period of time, triggering the ...

individuals with fibroblast growth factor receptor 2 (FGFR2) fusion/rearrangement. The single-arm, open-label registration study aims to assess the therapy’s safety, pharmacokinetics ...

Hutchmed has concluded enrolment of its multi-centre Phase II trial of fanregratinib (HMPL-453), a treatment for intrahepatic cholangiocarcinoma (IHCC) individuals with fibroblast growth factor ...

Impact of Insurance Status on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma This retrospective analysis included patients with cancer who had commercial ctDNA tests (K-Track, Gene ...

FGFR2 fusion occurs in 10-15% of IHCC patients ... (“IHCC”) patients with fibroblast growth factor receptor (“FGFR”)2 fusion/rearrangement. The study is a single-arm, multi-center, open ...

The study is a single-arm, multi-center, open-label, Phase II registration study to evaluate the efficacy, safety and pharmacokinetic of fanregratinib in treating advanced IHCC patients with FGFR2 ...

DelveInsight’s “BALVERSA Market Size, Forecast, and Market Insight Report” highlights the details around BALVERSA, a once-daily, oral fibroblast growth factor receptor (FGFR) kinase inhibitor.